311 results about "Nephrotic syndrome" patented technology

Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

Devices, systems and methods using feedback from sensors for the treatment of pathological conditions such as Kidney Disease (KD) alone, Heart Failure (HF) alone, KD with concomitant HF or cardiorenal diseases syndrome (CRS) are described. The devices, systems and methods monitor and gather patient information and administer one or more diuretic or natriuretic molecules.

The invention discloses a new traditional Chinese medicine composition for treating nephrotic syndrome and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following Chinese medicinal herbs such as American ginseng, ginseng, codonopsis pilosula, unprocessed astragalus mongholicus, Chinese yam, turtle shell, tortoise plastron, cornu cervi degelatinatum, fruit of Chinese wolfberry, root of Chinese trichosanthes, fruit of Chinese magnoliavine, seed of Chinese dodder, herba cistanche, Chinese caterpillar fungus, prepared rehmannia root, polygonum multiflorum, fructus ligustri lucidi, dried orange peel, myristica fragrans, fructus amomi, semen euryales, mangnolia officinalis, fructus chebulae, fructus rosae laevigatae, fructus alpiniae oxyphyllae, oyster, drynaria rhizome, dogwood, root-bark of Chinese wolfberry, phellodendron, fructus gardenia, white atractylodes rhizome, lucid asparagus, ophiopogon japonicus, herba epimedii, rhizoma anemarrhenae, root of kudzu vine and the like. The traditional Chinese medicine composition can be prepared into any one common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can remarkably improve symptoms of proteinuria, hypoalbuminemia, hematuresis, generaldropsy, listlessness, poor physical strength, inappetence, insomnia and amnesia, hypomnesis and the like of the patients suffering from the nephrotic syndrome and has accurate clinical treatment effect, remarkable treatment effect and rapid effect taking. Because of being combined by basically adopting medicinal and edible medicines specified in National Formulary, the invention has the advantages of low cost, basically no toxic and side effects and the like.

The present invention relates to a Chinese medicine compound for curing nephropathy syndrome, which is made from milk veteh, dried orange peel, salvia, dangshen, largehead atractylode, cortex eucommiae, motherwort herb, gordon euryale seed, parasite scurrula, coix seed, Chinese yam, imperatae rhizome, poria skin, epimedium powder, slenderstyle acanthopanax bark, cooked rehmannia root and / or acceptable carriers in pharmacology. The present invention also relates to a preparation method of the Chinese medicine compound. The Chinese medicine compound of the present invention has the effects of reinforcing the spleen and replenishing qi, removing heat and toxic substance, promoting diuresis and eliminating dampness, nourishing liver and kidney, etc., which is used for curing such symptoms as a large amount of albuminuria, serious edema, hypoproteinemia and hyperlipidemia caused by nephropathy syndrome.

The present invention relates to methods for treating and / or preventing podocytes related disorders and / or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and / or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and / or nephrotic syndrome.

The invention relates to a method for treating or preventing (including immunising against) post-weaning multisystemic wasting syndrome (PMWS) and / or porcine dermatitis and nephropathy syndrome (PDNS) in a subject comprising administering an effective amount of a pharmaceutical composition or immune modulator composition comprising a whole cell of a bacterium from one or more of the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, to said subject. In addition the method relates to the use of an immune modulator composition or a pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, in the manufacture of a medicament for the treatment or prevention of post-weaning multisystemic wasting syndrome (PMWS) and / or porcine dermatitis and nephropathy syndrome (PDNS).

The invention discloses a composite kidney-benefiting medicine and belongs to Chinese herbal composite medicine. The composite kidney-benefiting medicine comprises astragalus, angelica sinensis, red peony root, rhizoma chuanxiong, glossy privet fruit, eclipta, lalang grass rhizome, moutan bark, fructus kochiae and glycyrrhiza. The composite kidney-benefiting medicine can effectively cure pure simple hematuresis and hematuresis proteinuria, comprises immune globulin A (IgA) nephropathy, anaphylatic purpura nephritis, nephrotic syndrome, comprises nephritis type with hematuresis, can confront side effect of nephrotic syndrome which is cured by hormone, can play roles in promoting blood circulation to remove blood stasis and preventing and curing hypercoagulable state and has the advantages of being prominent in curative effect, convenient to take and good in taste.

The present invention is concerned with spiro-dihydrotetraazabenzoazulenes, i.e. spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes of formula I wherein R1, R2, R3, X, Y, Z, m and n are as described herein. The compounds according to the invention act as V1a receptor modulators and are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The invention provides a kit for detecting a serum anti-Annexin A2-IgG antibody. The detection kit of the invention adopts a target antigen Annexin A2 corresponding to an anti-Annexin A2-IgG antibodyof a primary nephrotic syndrome-related biomarker, uses human anti-tag peptide IgG as a standard substance for quantitative detection, and utilizes a biotin-labeled detection antibody and an enzyme-labeled streptavidin amplification system, thereby improving the accuracy and sensitivity of serum anti-Annexin A2-IgG antibody detection, and providing a better detection method for the diagnosis and treatment of primary nephrotic syndrome with the anti-Annexin A2-IgG antibody.

The present invention relates to heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis C virus infection and acne or other skin disorders.

The present invention is concerned with aryl- / heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein. The invention further provides methods for the manufacture of such compounds and pharmaceutical compositions containing them. The compounds according to the invention act as V1 a receptor modulators, and in particular as V1 a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention is concerned with heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein.The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

It is intended to provide a useful compound as an active ingredient of a preventive and / or therapeutic agent for rejection in the transplantation of an organ, bone marrow, or tissue, an autoimmune disease or the like which has an excellent S1P1 agonist effect. Because the compound of the invention has an S1P1 agonist effect, it is useful as an active ingredient of a therapeutic agent or a preventive agent for a disease caused by unfavorable lymphocytic infiltration, for example, an autoimmune disease such as graft rejection in the transplantation of an organ, bone marrow, or tissue or graft-versus-host disease, rheumatic arthritis, multiple sclerosis, systemic lupus erythematosus, nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, pulmonary disorder, asthma, atopic dermatitis, inflammatory bowel disease, atherosclerosis, or ischemia-reperfusion injury or an inflammatory disease, and further, a disease caused by the abnormal growth or accumulation of cells such as cancer or leukemia.

The present invention relates to a medicine for curing kidney diseases. Said medicine is a Chinese medicine capsule preparation made from 20 Chinese medicinal materials of cooked rehmannia root, silkworm, bupleurum root, Chinese yam, astragalus root, leech and others through the processes of conventional water and alcohol double extraction. Said medicine can be used for curing the diseases of acute and chronic nephritis, purpuric nephritis, hepatitis B related nephritis, lupoid nephritis, nephrotic syndrome, renal insufficiency and diabetic nephritis, etc. Its cure rate is up to 92%.

The present invention relates to methods for treating and / or preventing podocytes related disorders and / or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and / or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and / or nephrotic syndrome.

The Chinese medicine for curing chronic nephritis and nephrotic syndrome, specially for curing side effect resulted from application of hormone and rebound phenomenon produced after hormone extenuation and medicine withdrawal with good therapeutic effect is a water-paste pill made up by using 8 Chinese medicinal matterials of lonicera stem and leaf, astragalus root, flowery knotweed, dioscorea root, pseudotellaria root, licorice, placenta powder and rhubarb as raw material. Its therapeutic effect is reliable, and its effective rate is above 95%, and it has no toxic side effect.

The invention discloses a Chinese medicine for treating nephrotic syndrome. The Chinese medicine comprises glossy ganoderma, astragalus, fermentative cordycep fungal powder, serissa, centella asiatica, largehead atractylodes rhizome stir-fried with bran, cinnamomvine, safflower, motherwort herb, notoginseng root powder, lalang grass rhizome, common cephalanoplos herb, caulis sinomenii, pyrrosia leaf, prepared rehmannia root, dogwood, gordon euryale seed, rosa laevigata, tuckahoe, figwort root, platycodon gradiflorus, weeping forsythia and licorice. A decoction is prepared by the following steps of soaking the medicines except the fermentative cordycep fungal powder and notoginseng root powder in an appropriate amount of water in a decoction pot for 1 hour, wherein the water is slightly higher than a medicinal level; boiling the medicines over intense fire and then decocting over slow fire for 25 minutes and pouring a liquid medicine; decocting for the second time by the same method as a first-time decoction method, and pouring the liquid medicine; and mixing the two-time liquid medicine for later use. An administration method comprises the following steps of dividing the liquid medicine into two parts and taking the liquid medicine after being warmed at the night and in the morning; and dividing the fermentative cordycep fungal powder and the notoginseng root powder into two parts, and taking the fermentative cordycep fungal powder and the notoginseng root powder with the liquid medicine together. The Chinese medicine for treating the nephrotic syndrome is simple in preparation technologies and convenient to take, and has an obvious therapeutic effect on the nephrotic syndrome.

The present invention is concerned with aryl-cyclohexyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein. The invention further provides methods for the manufacture of such compounds and pharmaceutical compositions containing them. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists. The compounds are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention relates to a Chinese medicine composition for curing nephritic syndrome. Said Chinese medicine composition includes 5 Chinese medicinal materials of black soybean, astragalus root, atractylodes root, Chinese yam and Chinese angelica root. Said Chinese medicine composition can be made into tablet, capsule and granules preparation.

The invention discloses a traditional Chinese medicine for treating nephrotic syndrome, which is characterized by comprising the following components: 5-15g of glossy privet fruit, 10-20g of azuki bean, 6-12g of cordate houttuynia, 10-20g of plantain herb, 5-15g of root of hairy asiabell, 6-12g of Phellodendron amurense, 5-15g of Astragalus membranaceus, 5-15g of Chinese caterpillar fungus, and so on. The traditional Chinese medicine for treating nephrotic syndrome is prepared by a simple process, is convenient to take, and has remarkable treatment effect on nephrotic syndrome.

The invention discloses a compound oral Chinese patent medicament for treating gout, which consists of the following raw materials in percentage by weight based on crude medicaments: 5 to 20 percent of phellodendron, 5 to 20 percent of root of common peony, 5 to 30 percent of sevenlobed yam rhizome, 5 to 30 percent of desmodium, 3 to 10 percent of mastic, 3 to 10 percent of myrrh, 5 to 25 percent of suberect spatholobus stem, 5 to 20 percent of rhizoma atractylodis, 5 to 28 percent of oriental waterplantain rhizome, 5 to 20 percent of medicinal cyathula root, and 5 to 20 percent of root of largeleaf gentian. The invention discloses a preparation method for the medicament, and the formulations of the medicament are tablets, capsules, granules, oral liquid, dropping pills, and other common formulations. The compound oral Chinese patent medicament is used for treating acute and chronic gout, gouty arthritis, gouty stone, and gouty nephrotic syndrome, is a new medicament with obvious curative effects and safe administration for clinical treatment, and has significant application value.

The present invention relates to method of treating a patient with a condition involving increased vascular permeability or increased angiogenesis comprising administering to the patient a therapeutically effective amount of PEDF, PEDF 44 AA peptide, a homolog of the PEDF 44 AA peptide, a homolog of the PEDF 44 AA peptide wherein amino acid residues glutamate the (101) amino acid position, isoleucine at the (103) amino acid position, leucine at the (112) and serine at the (115) amino acid position are unchanged, or an agent that activates the PEDF receptor. Conditions for treatment include, but are not limited to, sepsis acute respiratory distress syndrome, nephrotic syndrome, diabetic neuropathy, preproliferative diabetic retinopathy, cancer or proliferative diabetic retinopathy.

The invention belongs to the technical field of model establishment and evaluation methods with an aim to solve problems about low flexibility and poor accuracy in an existing model establishment andevaluation method for the nephritic syndrome rats and provides a model establishment and evaluation method for the nephritic syndrome rats. Changes of endogenous metabolites in the urine of terminal products are analyzed by metabolomics, all 1 HNMR spectra are processed through MestReNova software to acquire integral data, statistical analysis of the content of 12 biomarkers is combined with, thechanges of the mean value of the 12 biomarkers in the urine before and after modeling reflect the change trend of the urine metabolite content in the nephritic syndrome rats, and models of nephritic syndrome are evaluated in a targeted manner. Dynamic body contours before and after modeling is reflected comprehensively, flexibly and systematically, rationality and scientific nature of model reproduction are comprehensively reflected, the reliable evaluation method for new drug development and pharmacological research is provided, and the method is efficient, rapid, noninvasive and high in specificity.

The invention relates to medical technology field, discloses a glucocorticoid synergist, and is characterized in adopting total ginsenoside as synergist. Its proportions are respectively as following: total ginsenoside 200mg-1200mg and dexamethasone 0.75-187.5mg; total ginsenoside 200mg-1200mg and betamethason 0.75-187.5mg; total ginsenoside 200-1200mg, and prednisone 5-1250mg, total ginsenoside 200-1200mg, and precortisyl 5-1250mg; total ginsenoside 200mg-1200mg, and urbason 4-1000mg; total ginsenoside 200-1200mg, and cortisone 25-6250mg; and total ginsenoside 200-1200mg, and hydrocortisone 20-5000mg.Total ginsenoside as glucocorticoid synergist can be used in the treatment of diseases requiring long term or a large amount of glucocorticoid such as systemic lupus erythematosus, nephrotic syndrome, polymyositis, and rheumatoid arthritis.

The utility model provides a Chinese traditional medicine for curing the chronic nephritis and nephropathy syndrome; the present invention consists of the following raw materials according to corresponding weight proportion of 10 to 50 portion of aweto, 10 to 50 portion of wild glossy ganoderma, 5 to 40 portion of Tibet safflower, 10 to 80 portion of gecko, 10 to 80 portion of cicada slough, 5 to 80 portion of ginseng, 5 to 50 portion of frankincense, 5 to 50 portion of myrrh, 5 to 80 portion of Tianshan snow lotus, 10 to 100 portion of cornel, 10 to 80 portion of prepared rhizome of rehmannia, 10 to 80 portion of root of red salvia, 10 to 80 portion of red peony, 5 to 70 portion of Paris chinensis, 5 to 80 portion of angelica, 10 to 100 portion of honeysuckle, 5 to 50 portion of leech, 5 to 50 portion of ledeboruiella root, 10 to 60 portion of oriental water plantain rhizome and 5 to 80 portion of gynura segetum. The preparation can take effect quickly and the curative effect is stable; with the preparation, the manifestation and the root cause of the disease can be cured; the preparation is convenient for taking and the dosage is less and the price is low.

The invention relates to the application of gentian in antiviral drug, while its gentian content is more than 50%, wherein the test has proved that gentian has activity resistant to CVB3 and HFRS. Therefore, the gentian can treat viral myocarditis and nephrotic syndrome. And it can be made into tablet, capsule, etc.

The invention relates to a Chinese medicinal preparation for treating a nephrotic syndrome and a preparation method. The raw materials of active ingredients of the prepared Chinese medicinal preparation consist of astragalus, eucommia bark, pyrrosia leaf, stem and leaf of assan crotalaria, pine leaf, stem and leaf of wallich pepper, rhizome of david anemone, lygodium japonicum, mosla scabra, herb of spanishneedles, rust-coloured crotalaria herb with root, gentianopsis barbata, cottonrose hibiscus root, root of cluster mallow, purple flower holly leaf and brittle falsepimpernel herb. The Chinese medicinal preparation has the effects of invigorating spleen, supplementing qi, tonifying kidney, strengthening body resistance, activating blood circulation to dissipate blood stasis, clearing heat and inducing diuresis, can be used for treating diseases such as chronic nephritis, pyelonephritis and nephrotic syndrome, has the characteristics of clear curative effect, safety, convenience, no toxic or side effect, quick response and low probability of relapse and has a total effective ratio of being over 90 percent on the treatment of the nephrotic syndrome.

The invention relates to a Chinese medicinal combination for treating nephrotic syndrome which is prepared from more than ten kinds of Chinese medicinal herbs including white atractylodes rhizome, raw astragalus root, red phaseolus bean and corn stigma.